Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05838885
Other study ID # TB2106GH
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 15, 2022
Est. completion date December 19, 2023

Study information

Verified date January 2024
Source Xiamen Amoytop Biotech Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore the dose-response relationship between pharmacokinetics and pharmacodynamics of Y- Shaped Pegylated growth hormone injection (YPEG-GH) in children with short stature (idiopathic short stature (ISS), small for gestational age (SGA), Turner syndrome (TS)). To evaluate its tolerability, safety and efficacy and to provide evidence for dose selection and titration for future clinical development and clinical application in these population.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date December 19, 2023
Est. primary completion date October 23, 2023
Accepts healthy volunteers No
Gender All
Age group 4 Years to 11 Years
Eligibility Inclusion Criteria: 1. Prepubertal (Tanner I), aged older than 4 years and younger than10 years for girls and 11 years for boys. 2. Body weight: 12kg = body weight = 50kg. 3. For children with idiopathic short stature: a) Birth length and weight were at the 10th percentile and above of normal reference values for infants of the same gestational age and sex; b) Height at screening was 2.0 standard deviations (SD) below the mean height for chronological age and sex c) Exclude other causes such as systemic diseases, other endocrine diseases, nutritional diseases, chromosomal abnormalities, skeletal dysplasia, psycho-emotional disorders, etc. were excluded d) GH peak =10.0ng/ml confirmed by two different drug GH provocation tests; e) Bone age (BA)-chronological age (CA) =1 year. 4. For children with small for gestational age: a) Birth length and weight were at the 10th percentile and below the normal reference values for infants if the same gestational age and sex; b) Gestational age at birth = 24 weeks; c) Height at screening was below -2 SD of the mean for the same age and sex, and please refer to the protocol annex 1 for height. 5. For children with Turner syndrome: a) Chromosome karyotype: 45, X; 45, X/46, XXqi; 45, X/46, XXr; 45, X/46, XX; 46, XXqi; 46, XXpi; 45, X/47, XXX; 46, XXp-; 45, X/46, XXp-; 46, XXq-; 45, x/46, XXq-; 45, X/46, XX/47, XXX, etc.; b) Having at least one specific physical characteristic: Including but not limited to low posterior hairline, facial skin nevus, neck flips, short neck, low ear position, small jaw, high palatal arch, shield chest, wide breast spacing, elbow ectropion, knee ectropion, short 4th and 5th metacarpal, nail dysplasia, scoliosis, ptosis, strabismus, cardiovascular system abnormalities such as aortic stenosis, bicuspid aortic valve, hypertension, and reproductive system abnormalities such as primary gonadal insufficiency, renal malformation, hypothyroidism and middle ear disease; c) The height at screening was below the mean -2SD of the same age and gender, and please refer to the protocol annex 1 for height. 6. Understands and signs the informed consent form voluntarily by the subject's parent(s) and/or legal guardian(s). And written assent of the subject is required if the subject is 8 years of age or older). Exclusion Criteria: 1. For children with small for gestational: confirmed or suspected Bloom syndrome. 2. For children with Turner syndrome: containing a Y chromosome or a fragment derived from a Y chromosome. 3. Children with closed epiphysis. 4. Children who diagnosed or highly suspected growth hormone deficiency (GHD), or other types of growth abnormalities: e.g., Noonan syndrome, Prader-Willi syndrome, Russell-Silver syndrome, etc. 5. Children who have previously received systemic growth-promoting therapy, including but not limited to rhGH, aromatase inhibitors, sex hormones, etc., for at least 1 month or longer. 6. Children who are now receiving or plan to receive the therapy of glucocorticoids, methylphenidate, and any other drugs that may have an effect on growth. 7. Children with abnormal values of liver and kidney function (ALT > 1.5 ULN, Cr > 1 ULN). 8. Concomitant with chronic hepatitis B, AIDS, tuberculosis, and any other chronic infectious disease. 9. Patients with severe allergic constitutions or allergic to growth hormone or its excipients such as mannitol, lysine, sodium chloride and other ingredients. 10. Patients with a previous history of malignancy or are currently suffering from active malignancy, including intracranial tumors. 11. Patients with abnormal glucose regulation (including abnormal fasting glucose and/or abnormal glucose tolerance) or diabetes. 12. Patients who are mentally ill or have a family history of mental illness. 13. Patients who are suffering from chronic systemic diseases, such as malnutrition, immunocompromised individuals, asthma, etc. 14. Patients with congenital intracranial hypertension. 15. Patients with slipped capital femoral epiphysis (SCFE). 16. Patients with scoliosis exceeding 15°; 17. Patients who have participated in any drug clinical study (as a subject) within 3 months prior to screening and have received a drug intervention 18. Patients who the investigators considered unfit for the study.

Study Design


Intervention

Drug:
YPEG-rhGH
YPEG-rhGH, 140µg/kg, s.c., once a week, for 52 weeks
YPEG-rhGH
YPEG-rhGH, 280µg/kg, s.c., once a week, for 52 weeks
rhGH
rhGH, 245µg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
rhGH
rhGH, 470µg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks

Locations

Country Name City State
China Children's Hospital, Capital Institute of Pediatrics Beijing
China Hunan Children's Hospital Changsha Hunan
China Chengdu Women's and Children's Central Hospital Chengdu Sichuan
China West China Second University Hospital, Sichuan University Chengdu Sichuan
China Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong
China The Third Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong
China Zhejiang Provincial People's Hospital Hangzhou Zhejiang
China The Fourth Affiliated Hospital of Anhui Medical University Hefei Anhui
China The Second Hospital of Anhui Medical University Hefei Anhui
China Jiangxi Provincial Children's Hospital Nanchang Jiangxi
China Children's Hospital of Nanjing Medical University Nanjing Jiangsu
China Sanya Central Hospital (Hainan Third People's Hospital) Sanya Hainan
China Children's Hospital of Shanghai Shanghai
China Children's Hospital of Soochow University Suzhou Jiangsu
China Tongji Hospital, Tongji Medical College of HUST Wuhan Hubei
China Wuhan Children's Hospital Wuhan Hubei
China Affiliated Hospital of Jiangnan University Wuxi Jiangsu
China The First Affiliated Hospital of Xiamen University Xiamen Fujian
China Henan Children's Hospital Zhengzhou Children's Hospital Zhengzhou Henan

Sponsors (2)

Lead Sponsor Collaborator
Xiamen Amoytop Biotech Co., Ltd. Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetic-area under plasma concentration versus time curve up to 52 weeks
Primary Pharmacokinetic-maximum serum concentration up to 52weeks
Primary Pharmacokinetic-time to reach the maximum plasma concentration up to 52 weeks
Primary Pharmacokinetic-terminal disposition phase half-life up to 52 weeks
Primary Pharmacokinetic-terminal elimination rate constant up to 52 weeks
Primary Pharmacokinetic-apparent clearance after extravascular administration up to 52 weeks
Primary Pharmacokinetic-apparent volume of distribution up to 52 weeks
Secondary Pharmacodynamics-the properties of Insulin-like growth facto1 and Insulin-like growth factor binding receptor 3. up to 57 weeks
Secondary Height velocity (HV, cm/year) At 52 weeks of treatment
Secondary Change of height velocity compared to baseline (?HV, cm/year) At 52 weeks of treatment
Secondary Height standard deviation according to chronological age (Ht SDS CA) At 52 weeks of treatment
Secondary Change in bone age At 52 weeks of treatment
Secondary Adverse events (including injection site reactions), changes from baseline in vital signs and laboratory tests up to 57 weeks
See also
  Status Clinical Trial Phase
Completed NCT01734486 - Growth Response in Girls With Turner Syndrome Phase 4
Completed NCT01678261 - X-chromosome Inactivation, Epigenetics and the Transcriptome N/A
Completed NCT01419249 - First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Phase 4
Completed NCT01518036 - Use of Somatropin in Turner Syndrome Phase 3
Recruiting NCT04948658 - Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
Completed NCT01563926 - Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Phase 3
Completed NCT02787486 - Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Completed NCT00877942 - Sex Differences in Early Brain Development; Brain Development in Turner Syndrome N/A
Completed NCT00825617 - Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy N/A
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Completed NCT01322165 - National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions N/A
Terminated NCT00419107 - Beta Cell Function in Women With Turner Syndrome N/A
Active, not recruiting NCT00625001 - Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome N/A
Completed NCT00029159 - The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Phase 3
Completed NCT01518062 - Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Phase 4
Completed NCT00471731 - Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure N/A
Completed NCT00256126 - Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Phase 4
Completed NCT03181230 - Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome